We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+7.53%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$20B
AUM Growth
-$1.4B
Cap. Flow
-$2.71B
Cap. Flow %
-13.53%
Top 10 Hldgs %
37.39%
Holding
342
New
43
Increased
66
Reduced
43
Closed
42

Top Buys

Rank Stock Value
1
ADBE icon
Adobe
ADBE
+$235M
2
HWM icon
Howmet Aerospace
HWM
+$189M
3
YMM icon
Full Truck Alliance
YMM
+$174M
4
GOOG icon
Alphabet (Google) Class C
GOOG
+$140M
5
ABBV icon
AbbVie
ABBV
+$133M

Top Sells

Rank Stock Value
1
TMUS icon
T-Mobile US
TMUS
+$588M
2
XLRN
Acceleron Pharma
XLRN
+$373M
3
NUAN
Nuance Communications, Inc.
NUAN
+$327M
4
WTW icon
Willis Towers Watson
WTW
+$319M
5
KSU
Kansas City Southern
KSU
+$319M

Sector Composition

Rank Sector Weight
1 Healthcare 32.06%
2 Industrials 13.15%
3 Technology 13.06%
4 Financials 12.22%
5 Communication Services 10.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRPT icon
51
Sarepta Therapeutics
SRPT
$1.98B
$75.6M 0.38%
839,009
+677,009
+418% +$57.9M
KRTX
52
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$72M 0.36%
550,000
-150,000
-21% -$19.4M
CHNG
53
DELISTED
Change Healthcare Inc. Common Stock
CHNG
$70M 0.35%
3,273,600
+535,000
+20% +$11.2M
UTHR icon
54
United Therapeutics
UTHR
$22B
$69.3M 0.35%
+320,760
New +$63M
RVMD icon
55
Revolution Medicines
RVMD
$44.9B
$69.2M 0.35%
2,750,000
– –
PTGX icon
56
Protagonist Therapeutics
PTGX
$9.99B
$65.6M 0.33%
1,917,134
-474,866
-20% -$15M
BRKR icon
57
Bruker
BRKR
$9.07B
$62.5M 0.31%
+745,266
New +$59.7M
AMRS
58
DELISTED
Amyris Inc.
AMRS
$58.8M 0.29%
10,859,811
-859,114
-7% -$8.02M
IMGO
59
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
$58.6M 0.29%
2,471,313
-200,000
-7% -$4.63M
ATTO
60
DELISTED
Atento S.A.
ATTO
$56.9M 0.28%
2,230,357
– –
JAZZ icon
61
Jazz Pharmaceuticals
JAZZ
$16.5B
$54.9M 0.27%
431,021
-143,886
-25% -$18.9M
ARNA
62
DELISTED
Arena Pharmaceuticals Inc
ARNA
$48.5M 0.24%
522,000
-134,548
-20% -$8.86M
BRMK
63
DELISTED
Broadmark Realty Capital Inc. Common Stock
BRMK
$45.7M 0.23%
4,850,000
-106,174
-2% -$1.05M
QGEN icon
64
Qiagen
QGEN
$9.1B
$45.2M 0.23%
767,708
-622,213
-45% -$35.7M
ZGNX
65
DELISTED
Zogenix, Inc.
ZGNX
$45M 0.22%
2,766,935
– –
ZEN
66
DELISTED
ZENDESK INC
ZEN
$44.8M 0.22%
+430,000
New +$46.1M
CRBU icon
67
Caribou Biosciences
CRBU
$178M
$44.7M 0.22%
2,963,448
– –
FATE icon
68
Fate Therapeutics
FATE
$279M
$44.3M 0.22%
757,425
-1,553,973
-67% -$88.1M
PACB icon
69
Pacific Biosciences
PACB
$420M
$41.9M 0.21%
2,045,488
+53,238
+3% +$1.28M
AGIO icon
70
Agios Pharmaceuticals
AGIO
$1.98B
$41.3M 0.21%
1,256,578
+437,811
+53% +$17.6M
RGEN icon
71
Repligen
RGEN
$10.2B
$36.1M 0.18%
136,245
+45,175
+50% +$12.2M
BIIB icon
72
Biogen
BIIB
$32B
$35.4M 0.18%
147,709
-23,150
-14% -$5.95M
CCXI
73
DELISTED
ChemoCentryx, Inc.
CCXI
$34.1M 0.17%
935,463
+549,463
+142% +$19.3M
GATE
74
DELISTED
Marblegate Acquisition Corp. Class A Common Stock
GATE
$29M 0.14%
+2,970,000
New +$29.1M
MNTV
75
DELISTED
Momentive Global Inc. Common Stock
MNTV
$28.4M 0.14%
+1,342,000
New +$29.5M
1 2
3
4 5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q4 2021 Portfolio in Review

As of Q4 2021, Thomas Steyer held 342 positions worth $20B, down 6.6% from $21.4B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Thomas Steyer withdrew a net $2.71B in Q4 2021, closing 42 positions and reducing 43 holdings. Its most notable exit was T-Mobile US, an estimated $588M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, up from 29% a quarter earlier, followed by Industrials and Technology.

Against the trend, Thomas Steyer opened a new position in Adobe worth $213M.

  • Thomas Steyer's largest Q4 2021 buy was Adobe: 376,000 shares worth $213M.
  • Thomas Steyer added most to Howmet Aerospace in Q4 2021, an estimated $189M increase.
  • Thomas Steyer's biggest Q4 2021 reduction was Nuance Communications, Inc., cutting an estimated $327M.
  • Thomas Steyer fully exited T-Mobile US in Q4 2021, selling an estimated $588M.
  • Thomas Steyer's ten largest holdings make up 37% of its $20B portfolio in Q4 2021.
  • Thomas Steyer opened 43 new positions and closed 42 in Q4 2021.
  • Thomas Steyer's portfolio value fell 6.6% quarter-over-quarter to $20B.

Based on Farallon Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.